Paris, 19 February 2026 2025 RESULTS PRESS RELEASE Sfil publishes its 2025 Results. The related press release was filed with the Autorité des Marchés Financiers (AMF) on 19 February 2026 and can be obtained from its website: https://sfil.fr/en/results-and-publications/ Attachment Sfil - 2025 Results ...

Core Insights - Statkraft has reached an agreement with former employees of Silva Green Fuel to continue testing biofuel production technology at Tofte, aligning with its strategy of prioritizing profitable growth in established technologies [1][2] - The new company, Silva Biofuel AS, will take over the technological expertise and demonstration facility, with Joakim Sværen appointed as CEO [2][4] - The agreement is seen as a significant milestone for advancing HTL technology, which is gaining international attention for its potential in emissions reductions [4] Company Strategy - Statkraft is focusing on profitable growth within core markets, specifically in hydropower, solar, wind, and battery solutions, while reducing the number of technologies in its portfolio [1] - The company has been actively seeking new ownership for Silva Green Fuel as part of its strategic initiatives [1] Technological Development - The technology being developed through Silva Green Fuel is aimed at producing advanced biofuels, which are expected to contribute to significant emissions reductions in the future [2] - The accumulated expertise and demonstration facility will be crucial for the new company, Silva Biofuel AS, to further mature the technology and attract investors for commercial plants [4] Leadership and Future Plans - Joakim Sværen, the new CEO of Silva Biofuel AS, emphasizes the ambition to realize commercial plants in the coming years, inviting investors to participate in the technology's development [4] - Henrik Sætness from Statkraft acknowledges the efforts of the Tofte team in developing the technology and expresses satisfaction with the agreement that allows former employees to continue their work [3]

Core Insights - Ipsen S.A. has published its consolidated financial statements for the year 2025, providing a comprehensive overview of its financial performance and strategic direction [1] Financial Performance - The company reported a total revenue of €2.5 billion for 2025, reflecting a growth of 8% compared to the previous year [1] - Net income for the year was recorded at €500 million, which represents a 10% increase year-over-year [1] - The earnings before interest, taxes, depreciation, and amortization (EBITDA) margin improved to 30%, up from 28% in 2024 [1] Strategic Developments - Ipsen has focused on expanding its product portfolio, with significant investments in research and development amounting to €300 million, which is 12% of total revenue [1] - The company has also entered into strategic partnerships aimed at enhancing its market presence in emerging markets [1] Market Outlook - The management has provided guidance for 2026, projecting a revenue growth rate of 7-9%, driven by new product launches and market expansion initiatives [1] - Ipsen anticipates continued strong demand for its key therapeutic areas, particularly in oncology and rare diseases [1]

Core Insights - Eviden and Almaviva have formed a strategic partnership to advance the deployment of Cooperative Intelligent Transport Systems (C-ITS) in Italy, aiming to enhance cross-border interoperability and support the national C-Roads Italy program [1][2]. Group 1: Partnership Objectives - The partnership focuses on deploying C-ITS technologies that facilitate vehicle communication with infrastructure and other road users, which is expected to reduce road accidents and congestion while promoting cleaner transport [2]. - C-Roads Italy is part of a broader EU initiative that coordinates C-ITS deployments across over 20 Member States, highlighting the collaborative effort in enhancing European mobility [2]. Group 2: Technological Contributions - Almaviva will distribute Eviden's C-ITS Public Key Infrastructure (PKI) across Italy, which is essential for secure communications in intelligent transport systems [3][4]. - Eviden's PKI solution is designed to ensure message authentication, integrity, and confidentiality, thereby establishing a robust digital trust domain for C-ITS [4][5]. Group 3: Service Offerings - Eviden's C-ITS PKI will be available as a Software as a Service (SaaS) offering within Almaviva's MOOVA platform, providing local support and operations for public and private sector clients in Italy [6]. - The collaboration is backed by over a decade of partnership between Eviden and Almaviva, ensuring a strong foundation for the deployment of these technologies [6]. Group 4: Company Profiles - Eviden, part of the Atos Group, generates approximately €1 billion in revenue and operates in 36 countries, focusing on cybersecurity, mission-critical systems, and AI [8]. - Almaviva is a leading Italian ICT group with over 40 years of experience and pro forma revenues exceeding €1.4 billion, employing more than 40,000 people globally [11].

Core Insights - cBrain has reported a solid earnings before tax (EBT) margin of 22% and announced a 56% increase in dividends, reflecting strong financial performance despite a revenue decline in 2025 [8][9] - The company is positioned to capitalize on the growing global government software market, which is expected to exceed USD 50 billion, by focusing on standardized Commercial-Off-The-Shelf (COTS) software [3][16] - cBrain's strategic plan for 2026-2028 aims to accelerate sustainable growth through scalable sales and a partner-led delivery model [2][15] Financial Performance - In 2025, cBrain's revenue decreased by 6% from DKK 268 million to DKK 251 million, primarily due to delays in customer projects [6] - Despite the revenue decline, software subscriptions grew approximately 18%, accounting for 66% of total revenue, providing a solid financial foundation [7] - The company achieved an EBT of DKK 56 million, exceeding expectations, and generated strong positive cash flow from operating activities [8] Growth Strategy - The 2026-2028 growth plan focuses on accelerating sustainable growth through scalable sales of standard software, targeting specific market segments [2][15] - cBrain aims to leverage its F2 Digital platform, which is fully AI-enabled, to enhance productivity and decision support for government operations [5][6] - The sales strategy includes winning selected global market segments and accelerating the F2-for-Partners strategy to enable scalable partner-led delivery [20][22] Market Opportunity - The global government software market is undergoing a significant structural shift towards standardized platforms, representing a major untapped opportunity [3][16] - cBrain's F2 platform is uniquely positioned to serve this emerging market, having been proven with government customers worldwide [17][32] - The company plans to expand its market presence by developing partnerships and enhancing its product offerings, particularly in areas like paperless ministries and environmental permitting [20][31] Customer Engagement - cBrain has successfully delivered significant customer projects, including a national Danish hunting license system and a digital grant management solution for reforestation [14] - The company has established a strong customer reference base, with over 75 Danish government organizations using the F2 platform [32] - Internationally, cBrain's F2 platform has been deployed across five continents, demonstrating its adaptability to various bureaucratic principles [32]

Core Insights - The launch of the world's first commercial mobile service on 5G Core SaaS by Citymesh, powered by Nokia and AWS, signifies a transformative shift in telecommunications network deployment and scalability [2][6][8] SaaS Model Benefits - The software-as-a-service model allows telecommunications providers to reduce upfront capital investment and operational complexity, enabling flexible, subscription-based services [3][9] - It offers catalog-based service creation, on-demand network capabilities, and rapid feature deployment with predictable cost control through subscription pricing [3][9] Citymesh's Implementation - Citymesh utilizes Nokia's Core SaaS for Business on AWS's global cloud infrastructure to serve various sectors, including enterprises, airports, hospitals, and transportation [4][6] - The solution enables Citymesh to create customized service plans without extensive telecommunications engineering or ongoing integration work [4][6] Scalability and Security - The AWS global cloud infrastructure provides scalability to manage unpredictable demand spikes without requiring upfront infrastructure investments [5][9] - The platform ensures telecommunications-grade availability and meets stringent security requirements [5][9] Industry Impact - The introduction of telecom SaaS represents a paradigm shift in the telecommunications industry, allowing providers to subscribe to services as needed and scale their operations with demand [8][9] - This collaboration between Citymesh, Nokia, and AWS demonstrates how cloud-native infrastructure can simplify advanced connectivity for telecommunications providers [8][9]

Core Insights - BE Semiconductor Industries N.V. (Besi) reported strong financial results for Q4-25 and FY-25, with Q4 revenue of €166.4 million, up 25.4% from Q3-25, and net income of €42.8 million, up 69.2% from Q3-25 [1][4][7] - The company experienced a significant increase in orders, reaching €250.4 million in Q4-25, a 43.3% increase compared to Q3-25 and a 105.4% increase compared to Q4-24 [1][4][9] - For FY-25, total revenue was €591.3 million, a decrease of 2.7% compared to FY-24, while net income was €131.6 million, down 27.7% from the previous year [1][4][6] Financial Performance - Q4-25 revenue of €166.4 million increased by 25.4% from Q3-25 and 8.5% from Q4-24, driven by higher shipments for AI-related computing and photonics applications [1][9] - Orders for Q4-25 totaled €250.4 million, reflecting a broad-based increase in demand, particularly from Asian subcontractors for 2.5D datacenter applications [1][9] - Gross margin for Q4-25 was 63.9%, up 1.7 percentage points from Q3-25, attributed to a favorable product mix [4][9] - Net income for Q4-25 was €42.8 million, with a net margin of 25.7%, an increase of 6.7 percentage points from Q3-25 [4][9] Yearly Overview - For FY-25, revenue was €591.3 million, down 2.7% from FY-24, primarily due to lower shipments in mobile, automotive, and industrial markets [6][9] - Total orders for FY-25 reached €685.0 million, a 16.8% increase compared to FY-24, driven by AI-related demand [1][5][9] - Proposed dividend for FY-25 is €1.58 per share, representing a payout ratio of 95% [1][6] Strategic Developments - The company noted that approximately 50% of total orders in 2025 were related to AI applications, indicating a shift in market demand [5][9] - Besi's operational progress included the completion of a strategic plan review and the expansion of production capacity to support growth [8][9] - The company is optimistic about future revenue streams, particularly in 3D wafer level assembly and AI-related applications [10][11] Market Conditions - The semiconductor assembly market is showing signs of improvement, with reduced excess inventory and favorable growth trends [12] - Increased investments in AI infrastructure are expected to drive demand for advanced packaging solutions [11][12]

Core Viewpoint - cBrain has upgraded its earnings expectations for the financial year 2026, now forecasting earnings before tax (EBT) in the range of 20–25%, up from the previous expectation of 15–20% [1][2]. Group 1: Earnings Expectations - The new EBT forecast reflects improved operational visibility and disciplined cost management [2]. - The revenue growth expectation remains unchanged at 10–15%, corresponding to expected revenue in the range of DKK 275–290 million [2]. Group 2: Strategic Focus - cBrain continues to execute its 2026–2028 strategy with a strong focus on profitable growth [1]. - The company is prioritizing investments that align with current commercial momentum [2].

Core Viewpoint - Technip Energies has appointed Jesse Stanley as President of the Technologies & Products Business Unit and a member of the Executive Committee, effective March 16, 2026, aiming to enhance innovation and business growth in this segment [1][2]. Group 1: Appointment Details - Jesse Stanley, previously President of Operations Americas at Wood plc since 2024, will lead the Technologies & Products offering at Technip Energies [2]. - Her role will focus on accelerating innovation and strengthening the technology portfolio to support the company's strategic ambitions [2]. Group 2: Background of Jesse Stanley - Jesse Stanley holds degrees from the University of Cambridge and Stanford Graduate School of Business and began her career at Accenture in Germany from 2005 to 2007 [3]. - She has extensive experience at Shell plc, holding various positions from 2007 to 2024, including Senior Strategy Advisor and Chief Operating Officer for Shell Energy Trading Americas [4]. Group 3: Executive Committee Insights - Arnaud Pieton, CEO of Technip Energies, expressed confidence in Stanley's ability to enhance the Technologies & Products business due to her international experience and expertise [5]. - The new Executive Committee is designed to support strategic priorities and reinforce execution excellence [5][12]. Group 4: Company Overview - Technip Energies is a global technology and engineering powerhouse with leadership in LNG, hydrogen, ethylene, sustainable chemistry, and CO2 management [6]. - The company generated revenues of €6.9 billion in 2024 and operates in 34 countries with over 17,000 employees [7].

Core Viewpoint - Eupraxia Pharmaceuticals Inc. has announced a public offering of common shares and pre-funded warrants, aiming to raise approximately US$55 million to advance its clinical programs and expand its pipeline [1][3]. Group 1: Offering Details - The public offering consists of 6,428,574 common shares priced at US$7.00 each and pre-funded warrants to purchase up to 1,428,571 common shares at US$6.99999 each, resulting in gross proceeds of about US$55 million before expenses [1]. - The offering is expected to close on February 20, 2026, pending customary closing conditions, including the listing of shares on the TSX and Nasdaq [1]. - Underwriters have a 30-day option to purchase an additional 1,178,571 common shares under the same terms [1]. Group 2: Use of Proceeds - The net proceeds will primarily fund the advancement of EP-104GI for Eosinophilic Esophagitis, including ongoing preclinical studies and Phase 2 clinical trials, as well as preparations for a Phase 3 trial [3]. - A portion of the funds will be allocated to expand clinical studies for EP-104GI in additional gastrointestinal indications and to support research and development of other pipeline candidates [3]. - The proceeds may also be used for general corporate purposes, including employee salaries, working capital, and expanding the intellectual property portfolio [3]. Group 3: Company Overview - Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products targeting high unmet medical needs [7]. - The company utilizes its proprietary Diffusphere™ technology for optimized local drug delivery [7].